A pilot trial can succeed at its intended decision without proving that treatment outperforms placebo. In a 2016 methamphetamine-use-disorder study, “success” meant that a combination of naltrexone and bupropion showed enough promise to justify further investigation under a prespecified two-stage design. Understanding that purpose prevents its response percentage from being mistaken for a definitive treatment effect.
Who received which intervention?
Mooney and colleagues enrolled 49 adults across three US sites. Participants met criteria for severe methamphetamine-type stimulant use disorder and reported methamphetamine use on at least 20 of the preceding 30 days. Screening also required repeated methamphetamine-positive urine results. This was a selected, treatment-seeking population, rather than a sample of everyone with a positive toxicology test.
The intervention lasted eight weeks. Extended-release naltrexone, 380 mg by injection, was administered at weeks 1 and 5. Oral extended-release bupropion increased from 150 mg/day on days 1–2 to 300 mg/day on days 3–4 and 450 mg/day from day 5, with a reduction to 300 mg permitted for tolerability. A taper followed during week 9. These are historical research procedures, not prescribing instructions.
Were the two stages different treatment groups?
No. Stage 1 enrolled 20 participants; stage 2 added 29. Both stages used the same intervention and procedures. Stage 2 would proceed only if at least three stage-1 participants met the response criterion. If fewer did, the study would stop for insufficient promise.
Five stage-1 participants responded, allowing recruitment to continue. Six more responded in stage 2. Thus 11 of 49 met the endpoint, exceeding the final threshold of nine responders. The stages were sequential recruitment decisions, not randomized active and placebo arms, and not a randomized comparison of different treatment durations.
What counted as a response?
A responder needed at least six methamphetamine-negative urine drug screens among eight scheduled during weeks 5–8, including a final negative screen obtained in week 8. Central-laboratory results used a 500 ng/mL cutoff. Study staff did not receive the treatment-phase urine results, reducing one potential source of assessment influence.
This was a defined pattern of urine results during a specified four-week evaluation period. It did not require every sample to be negative, demonstrate uninterrupted abstinence between collections, or establish recovery after medication ended. A negative classification under that cutoff also should not be equated with an analytically established concentration of zero.
Why does the paper report 24% when 11 divided by 49 is about 22%?
The raw proportion is approximately 22.4%. The authors separately reported a design-adjusted unbiased estimate of 24%, calculated using methods appropriate to the two-stage procedure. They reported a 95% lower confidence limit of 13% and a trial p-value of 0.0075.
Those numbers should retain their labels. The lower confidence limit is not a complete two-sided interval. The p-value addresses the design’s hypothesized response benchmark, which assumed a null response rate of 10% or less. It is not a p-value from a contemporaneous randomized comparison with placebo: this pilot had no placebo group.
What else accompanied the medication?
Participants attended clinic twice weekly for observed oral dosing, urine collection, assessments and medical management. Smartphone videos documented take-home dosing, and compensation included payments for qualifying adherence videos. Blood measurements of bupropion and hydroxybupropion provided additional adherence information.
Those procedures helped establish feasibility and medication exposure. They also mean that the observed outcome arose within an intensive research setting. The pilot cannot isolate the contribution of medication from expectations, contact, adherence support or participant selection. It likewise cannot separate the independent contributions of naltrexone and bupropion because everyone received the combination.
Did meeting the research threshold establish safety?
No. Forty-five participants reported 249 treatment-emergent adverse events, and two participants had serious events: convulsion and acute amphetamine intoxication. The authors attributed one generalized seizure to bupropion. It occurred four days after the participant reached the 450 mg maintenance dose; the discussion also identified other possible factors affecting seizure susceptibility.
A small pilot can reveal important adverse events while remaining unable to estimate uncommon risks precisely. Its positive decision to continue development is therefore not a declaration that treatment is risk-free.
How should the result be explained to a client?
The defensible historical conclusion is that the regimen crossed a predefined signal threshold and warranted a more definitive test. Its result is not a cure rate, an individualized prognosis or a placebo-adjusted benefit estimate. Comparisons with later trials must preserve differences in design, dosing schedules, population and response rules instead of comparing percentages as though they measured the same outcome.
Scientific source
Mooney LJ, Hillhouse MP, Thomas C, et al. Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. Journal of Addiction Medicine. 2016;10(4):236–243. doi:10.1097/ADM.0000000000000218. Historical open-label human pilot study; original research-based commentary.
Leave a Reply